Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR 2,233.30
+42.25 (1.93%)
At close: Jul 31, 2026
Glenmark Pharmaceuticals Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 177,366 | 169,825 | 133,633 | 126,454 | 116,556 | 123,049 |
Revenue Growth | 32.94% | 27.08% | 5.68% | 8.49% | -5.28% | 12.44% |
Gross Profit Gross Profit Growth | 127,589 | 122,350 | 88,383 | 80,665 | 72,448 | 77,568 |
Operating Income Operating Income Growth | 41,800 | 39,989 | 19,069 | 14,457 | 11,382 | 18,400 |
Net Income Net Income Growth | 17,979 | 13,619 | 10,471 | -15,017 | 2,972 | 9,417 |
Earnings Per Share EPS Growth | 63.69 | 48.24 | 37.11 | -53.22 | 10.53 | 33.37 |
EPS Growth | 138.55% | 30.00% | - | - | -68.43% | -2.93% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 44,845 | 33,967 | 40,461 | 43,809 |
North America North America Growth | 30,172 | 30,943 | 31,481 | 32,035 |
Europe Europe Growth | 30,063 | 25,556 | 20,056 | 20,047 |
Latin America and Rest of The World Latin America and Rest of The World Growth | 28,138 | 27,666 | 23,834 | - |
Total Total Growth | 133,217 | 118,131 | 115,832 | 123,049 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 11,763 | 11,763 | 16,821 | 16,641 | 11,683 | 14,163 |
Total Debt Total Debt Growth | 5,935 | 5,935 | 24,727 | 12,309 | 46,079 | 39,620 |
Net Cash (Debt) Net Cash Growth | 5,827 | 5,827 | -7,906 | 4,331 | -34,396 | -25,458 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 20.64 | 20.64 | -28.02 | 15.35 | -121.90 | -90.22 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 34,450 | -8,276 | -2,654 | 6,254 | 11,087 |
Capital Expenditures CapEx Growth | - | -13,577 | -7,496 | -8,984 | -6,078 | -7,901 |
Free Cash Flow Free Cash Flow Growth | - | 20,873 | -15,772 | -11,638 | 176.29 | 3,185 |
Free Cash Flow Growth | - | - | - | - | -94.47% | -10.64% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 71.94% | 72.05% | 66.14% | 63.79% | 62.16% | 63.04% |
Operating Margin | 23.57% | 23.55% | 14.27% | 11.43% | 9.77% | 14.95% |
Pretax Margin | 14.28% | 11.69% | 10.47% | 0.29% | 2.06% | 11.71% |
Profit Margin | 10.14% | 8.02% | 7.84% | -11.88% | 2.55% | 7.65% |
FCF Margin | - | 12.29% | -11.80% | -9.20% | 0.15% | 2.59% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 5.000 | 5.000 | 2.500 | 2.500 | 2.500 | 2.500 |
Dividend Per Share Growth | 0% | 100.00% | 0% | 0% | 0% | 0% |
Dividend Yield | 0.23% | 0.23% | 0.16% | 0.26% | 0.54% | 0.57% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 35.06 | 44.17 | 41.53 | - | 44.11 | 13.24 |
P/FCF Ratio | 30.20 | 28.82 | - | - | 743.80 | 39.15 |
PS Ratio | 3.55 | 3.54 | 3.25 | 2.14 | 1.13 | 1.01 |